+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06667908

Randomized Study of JNJ-90301900 with Chemoradiation Followed by Durvalumab in Advanced Non-Small Cell Lung Cancer

Led by Johnson & Johnson Enterprise Innovation Inc. · Updated on 2026-11-03

130

Participants Needed

45

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether adding JNJ-90301900 to standard treatment with platinum-based chemotherapy and radiation therapy, followed by consolidation immunotherapy, can improve the rate of tumor shrinkage in people with locally advanced, unresectable stage III non-small cell lung cancer. This is a phase 2 randomized trial aiming to assess the feasibility, safety, and effectiveness of JNJ-90301900 injections combined with the usual treatments. Participants are randomly assigned to receive JNJ-90301900 injected directly into tumors or lymph nodes at different doses along with concurrent chemotherapy and radiation therapy, followed by immunotherapy with durvalumab. Another group receives the standard concurrent chemoradiation followed by durvalumab without JNJ-90301900 to compare outcomes. Chemotherapy includes carboplatin and paclitaxel delivered intravenously, and radiation is given by intensity modulated radiation therapy. Throughout the study, participants undergo assessments of tumor response using imaging and clinical evaluations over up to two years. Researchers monitor safety through physical exams, lab tests, and recording adverse events. The main outcome is the objective response rate, measuring how many participants experience tumor shrinkage. Secondary outcomes include progression-free survival, duration of response, and other disease control measures. Participants will be followed for up to two years and two months to evaluate treatment effects and safety.

CONDITIONS

Brief Title

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here